- $204.76bn
- $227.44bn
- $45.81bn
- 85
- 28
- 50
- 54
REG - AstraZeneca PLC - AstraZeneca settles Nexium liability litigations
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Dato-DXd improved PFS in breast cancer
AnnouncementREG - AstraZeneca PLC - Alexion completes Pfizer gene therapy agreement
AnnouncementREG - AstraZeneca PLC - Enhertu recommended in EU for HER2-mutant NSCLC
AnnouncementREG - AstraZeneca PLC - Fasenra Phase III EGPA trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - Update on US review of Ultomiris for NMOSD
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Alexion enters gene therapy agreement with Pfizer
AnnouncementREG - AstraZeneca PLC - Half-year Report
AnnouncementREG - AstraZeneca PLC - Beyfortus approved in US for infant RSV prevention
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Dato-DXd significantly improved PFS in lung cancer
AnnouncementREG - AstraZeneca PLC - nirsevimab recommended for infant RSV protection
AnnouncementREG - AstraZeneca PLC - AstraZeneca agreement with Quell Therapeutics
AnnouncementREG - AstraZeneca PLC - Imfinzi improved pCR in gastric and GEJ cancers
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
Announcement